Vaccinia Virus (VV) is a viral vector used in pre-clinical and clinical studies of active cancer immunotherapeutic strategies. CD40 receptor is expressed on a broad range of immune cells. Furthermore, CD40 expression has been reported also in nearly all B-cell malignancies and solid tumors of different origins. Interestingly, CD40 ligation might result in different biological responses depending on the cell types and to the strength of CD40 ligand (CD40L; CD154)-mediated stimulation of CD40 receptor. Based on this background, we have generated a replication incompetent CD40 ligand-expressing recombinant vaccinia virus (rVV40L) and we have investigated its antitumor activity. Notably, rVV40L-infection resulted in an improvement of (i) the antigen presenting capacity of CD40+ nonprofessional CD14+ monocytes leading (ii) to the rapid expansion and differentiation of human naïve CD8+ T cells into central memory T cells (TCM) specific for tumor associated antigens (TAAs), (ii) the induction of apoptotic effects on CD40+ established tumor cell lines of different origin and (iii) the antitumor activity, TNF-mediated, of macrophages. Collectively, these data indicate that rVV40L can be considered a successful viral vector for cancer immunotherapy according to its multiple mechanisms of action.
Citation Format: Emanuele Trella. Multipotency of a CD40L-expressing recombinant vaccinia virus [abstract]. In: Proceedings of the Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; 2016 Sept 25-28; New York, NY. Philadelphia (PA): AACR; Cancer Immunol Res 2016;4(11 Suppl):Abstract nr A016.
- ©2016 American Association for Cancer Research.